Mizuho Markets Americas LLC Buys 72,765 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Mizuho Markets Americas LLC raised its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 22.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 399,065 shares of the biotechnology company’s stock after buying an additional 72,765 shares during the period. Sarepta Therapeutics comprises approximately 1.0% of Mizuho Markets Americas LLC’s investment portfolio, making the stock its 22nd biggest position. Mizuho Markets Americas LLC’s holdings in Sarepta Therapeutics were worth $49,839,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Farallon Capital Management LLC lifted its stake in Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after acquiring an additional 1,243,427 shares during the period. Principal Financial Group Inc. increased its stake in shares of Sarepta Therapeutics by 693.7% in the second quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock worth $57,356,000 after acquiring an additional 317,277 shares during the period. Canada Pension Plan Investment Board raised its stake in shares of Sarepta Therapeutics by 2,257.8% during the 1st quarter. Canada Pension Plan Investment Board now owns 240,500 shares of the biotechnology company’s stock valued at $31,135,000 after buying an additional 230,300 shares during the last quarter. Rhumbline Advisers lifted its holdings in Sarepta Therapeutics by 146.3% in the second quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company’s stock valued at $42,809,000 after acquiring an additional 160,942 shares during the period. Finally, Blair William & Co. IL lifted its stake in shares of Sarepta Therapeutics by 303.7% in the 2nd quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company’s stock valued at $27,537,000 after purchasing an additional 131,112 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $104.54 on Friday. The company has a market capitalization of $9.99 billion, a P/E ratio of 83.63 and a beta of 0.81. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a 50-day simple moving average of $123.72 and a 200 day simple moving average of $132.33. Sarepta Therapeutics, Inc. has a fifty-two week low of $78.67 and a fifty-two week high of $173.25.

Analyst Ratings Changes

SRPT has been the subject of a number of recent analyst reports. Robert W. Baird cut their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 price objective on the stock. Barclays reduced their price target on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Citigroup lowered their price target on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Finally, Raymond James reiterated an “outperform” rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a report on Thursday, October 10th. One research analyst has rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $181.33.

Insider Activity

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. The trade was a 14.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.